SCHEMBL1322602

SCHEMBL1322602

O=C(/C=C/c1ccc(/C=C/C(=O)c2ccc(F)cc2)c(F)c1)NO

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 2/20 0.61
HDAC1 Q13547 7/20 0.59
HDAC4 P56524 6/20 0.59
HDAC3 O15379 5/20 0.56
HDAC7 Q8WUI4 5/20 0.56
HDAC2 Q92769 5/20 0.56
HDAC10 Q969S8 5/20 0.56
HDAC11 Q96DB2 5/20 0.56
HDAC8 Q9BY41 5/20 0.56
HDAC6 Q9UBN7 5/20 0.56
HDAC9 Q9UKV0 5/20 0.56
HDAC5 Q9UQL6 5/20 0.56
CYP1A1 P04798 2/20 0.54
CYP1B1 Q16678 2/20 0.54
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
MAPT P10636 3/20 0.50
MAOB P27338 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1322603 1.00 TNFRSF1A (0.61) TNFRSF1AHDAC1HDAC4HDAC3HDAC7
SCHEMBL1319922 0.90 HDAC1 (0.56) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL1322218 0.90 MAPT (0.58) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL1322214 0.90 MAPT (0.58) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL1319923 0.90 HDAC1 (0.56) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL1320344 0.90 HDAC4 (0.72) TNFRSF1AHDAC1HDAC4HDAC3HDAC7
SCHEMBL1320011 0.90 HDAC4 (0.72) TNFRSF1AHDAC1HDAC4HDAC3HDAC7
SCHEMBL1320010 0.90 HDAC4 (0.72) TNFRSF1AHDAC1HDAC4HDAC3HDAC7
SCHEMBL1320345 0.90 HDAC4 (0.72) TNFRSF1AHDAC1HDAC4HDAC3HDAC7
SCHEMBL1322283 0.88 TNFRSF1A (0.58) TNFRSF1AHDAC1HDAC4HDAC3HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP claimed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP claimed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US claimed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US claimed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US claimed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US claimed
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP disclosed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS HDAC1, HDAC3, HDAC11 TNFRSF1A 1967/4885HDAC1 1/4885HDAC4 11/4885
US-20080096889-A1 Histone Deacetylases Inhibitors HDAC1, HDAC3, HDAC11 TNFRSF1A 2052/4885HDAC1 1/4885HDAC4 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.